Jubilant gets USFDA nod for Drax Exametazime
New Delhi: Drug firm Jubilant Life Sciences on Monday said it has received new drug application approval from the US health regulator for Drax Exametazime.
Jubilant Pharma Ltd, a wholly-owned subsidiary of the company, through its Canada-based arm Jubilant Draximage Inc has received new drug application (NDA) approval from the United States Food and Drug Administration (USFDA) for Drax Exametazime, Jubilant Life Sciences said.
"This approved NDA is indicated for leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease," it said in a BSE filing.
This is the sixth approval the company has received from the USFDA during the current financial year, it added.
approvalDrax Exametazimeinflammatory bowel diseaseintra-abdominal infectionJubilantJubilant Draximage IncJubilant Life Sciencesleukocyte labeled scintigraphyNew Drug ApplicationUSFDAwhite blood cells
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd